Good prognostic factor in patients with nonmetastatic nasopharyngeal carcinoma: Programmed death ligand-1 expression in tumor cells
| Autor: | Ayse Ocak Duran, Nalan Akyürek, Elif Acar, Olcay Kandemir, Hayriye Şahinli, Ahmet Ozet, Mukaddes Yılmaz, Nuriye Ozdemir, Sezer Kulaçoǧlu, O Berna Ç Öksüzoǧlu, Gokhan Ucar |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Oncology
Adult Male medicine.medical_specialty Adolescent medicine.medical_treatment Biopsy Kaplan-Meier Estimate Risk Assessment B7-H1 Antigen Young Adult Cancer immunotherapy Internal medicine Nasopharynx medicine Biomarkers Tumor Humans Radiology Nuclear Medicine and imaging Clinical significance Aged Retrospective Studies Nasopharyngeal Carcinoma Proportional hazards model business.industry Hazard ratio Nasopharyngeal Neoplasms General Medicine Middle Aged medicine.disease Ligand (biochemistry) Prognosis Immunohistochemistry Confidence interval Nasopharyngeal carcinoma Female business Follow-Up Studies |
| Zdroj: | Journal of cancer research and therapeutics. 16 |
| ISSN: | 1998-4138 |
| Popis: | Purpose: Programmed death ligand-1 (PD-L1) is the main ligand for programmed death-1 (PD-1), and is one of the major targets for cancer immunotherapy. Only a few studies are available for the clinical significance of PD-1/PD-L1 in nasopharyngeal carcinoma (NPC). There is a controversial association between PD-L1 expression and survival in NPC. This study aimed at defining any potential association between PD-L1 expression in tumor cells (TCs) and prognosis in NPC. Patients and Methods: A total of seventy NPC patients treated between January 2008 and December 2016 were included in the study. PD-L1 expression was assessed by immunohistochemistry (IHC) in tumor specimens. The IHC assay was considered positive if >= 5% of TCs are stained. Clinicopathological variables were documented. Variables included in the analysis were PD-L1 expression, clinicopathological characteristics, and prognosis. Results: The estimated 5-year overall survival (OS) rate was 62%. Nearly 55.7% (n = 39) of the TCs tested positive for PD-L1 expression. No associations were found between the level of PD-L1 in TCs and clinicopathological characteristics. Comparisons between patients with PD-L1-positive tumors and PD-L1-negative tumors revealed that OS was statistically significantly longer in patients with PD-L1-positive tumors as assessed by the univariate Cox regression analysis (hazard ratio [HR], 0.378; 95% confidence interval, 0.158-0.905; P = 0.029) and Kaplan-Meier curves (P = 0.023). Conclusion: PD-L1 expression is an important prognostic factor in NPC. PD-L1 expression positively correlates with survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|